PDCD1 Human
Programmed Cell Death 1, Systemic Lupus Erythematosus Susceptibility 2, Protein PD-1, HPD-1, PD1, Programmed Cell Death 1 Protein, Programmed Cell Death Protein 1, CD279 Antigen, CD279, HPD-L, HSLE1, SLEB2, PD-1.
Greater than 90.0% as determined by SDS-PAGE.
Description
PDCD1 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 392 amino acids (21-170a.a.) and having a molecular mass of 44.0kDa (Molecular size on SDS-PAGE will appear at approximately 40-57kDa).
PDCD1 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Programmed Cell Death 1, Systemic Lupus Erythematosus Susceptibility 2, Protein PD-1, HPD-1, PD1, Programmed Cell Death 1 Protein, Programmed Cell Death Protein 1, CD279 Antigen, CD279, HPD-L, HSLE1, SLEB2, PD-1.
ADPPGWFLDS PDRPWNPPTF SPALLVVTEG DNATFTCSFS NTSESFVLNW YRMSPSNQTD KLAAFPEDRS QPGQDCRFRV TQLPNGRDFH MSVVRARRND SGTYLCGAIS LAPKAQIKES LRAELRVTER RAEVPTAHPS PSPRPAGQFQ TLVLEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGKHHHH HH.
Product Science Overview
PD-1 was first identified in 1992 by Yasumasa Ishida, Tasuku Honjo, and colleagues at Kyoto University during a screen for genes involved in apoptosis . The protein belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells . PD-1 binds to two ligands, PD-L1 and PD-L2, which are also part of the immune checkpoint pathway .
PD-1 functions as an inhibitory immune checkpoint that prevents T cell overstimulation and host damage . It promotes apoptosis (programmed cell death) of antigen-specific T-cells in lymph nodes and reduces apoptosis in regulatory T cells (anti-inflammatory, suppressive T cells) . This dual mechanism helps maintain immune homeostasis and prevents the immune system from attacking the body’s own tissues .
PD-1 plays a significant role in cancer immunotherapy. Tumors can exploit the PD-1 pathway to evade immune detection by expressing PD-L1, which binds to PD-1 on T cells and inhibits their activity . PD-1 inhibitors, a new class of drugs, block this interaction and activate the immune system to attack tumors . These inhibitors have shown promising results in treating various types of cancer, including melanoma, lung cancer, and renal cell carcinoma .
Recombinant human PD-1 is a form of the protein that is produced through recombinant DNA technology. This involves inserting the PDCD1 gene into a suitable expression system, such as bacteria or mammalian cells, to produce the protein in large quantities . Recombinant PD-1 is used in research and therapeutic applications to study its function and develop new treatments for diseases involving the immune system .
Recombinant PD-1 and PD-1 inhibitors are used in clinical settings to treat various cancers. These treatments have been shown to improve patient outcomes by enhancing the immune system’s ability to recognize and destroy cancer cells . Additionally, recombinant PD-1 is used in research to better understand the mechanisms of immune regulation and develop new therapeutic strategies .
